ToPCourT protocol: a phase II trial of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced/unresectable or metastatic triple-negative breast cancer [0.03%]
ToPCourT方案Ⅱ期临床研究：德鲁替康联合派姆单抗、吉西他滨和卡铂治疗局部晚期/不可切除或转移性三阴乳腺癌的一项Ⅱ期临床研究
Megan B Sears-Smith,Ashley Matusz-Fisher,James T Symanowski et al.
Megan B Sears-Smith et al.
Triple-negative breast cancer (TNBC) is a clinically aggressive and difficult to treat malignancy. It has a poorer prognosis when compared to the hormone receptor (HR)-positive and human epidermal growth factor receptor type 2 (HER2)-positi...
Systematic review of reflex biomarker testing and its influence on diagnostic and treatment timelines in cancer pathways [0.03%]
系统审查反射生物标志物检测及其对癌症途径诊断和治疗时间表的影响
Christopher Felix Brewer,Edward Donnely
Christopher Felix Brewer
Background: Reflex biomarker testing, where molecular assays are automatically requested at diagnosis, has been proposed to accelerate cancer care. However, its operational and clinical impact across tumor types has not b...
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib [0.03%]
POIESIS研究：鲁索利替尼治疗反应不佳的jak抑制剂初治骨髓纤维化患者的添加navtemadlin疗法三期临床试验
Pankit Vachhani,Abdulraheem Yacoub,Raajit Rampal et al.
Pankit Vachhani et al.
Most myelofibrosis (MF) patients treated with ruxolitinib fail to achieve optimal response (i.e., spleen volume reduction ≥35% [SVR35] and improvement in total symptom score ≥50% [TSS50], and instead experience suboptimal reductions in sp...
MISTOSUS: a phase II trial of Viscum album extract adjuvant therapy for relapsed resectable osteosarcoma [0.03%]
英国临床肿瘤学会年会——米斯特索斯：艾叶提取物联合治疗复发性可切除骨肉瘤II期试验
Katharine Offer,Marcus Reif,Clark Andersen et al.
Katharine Offer et al.
Relapsed resectable osteosarcoma carries a dismal prognosis of 30% 12-month post-relapse event-free survival (PREFS-12). Surgery remains the primary therapy for metastatic pulmonary osteosarcoma with the role for adjuvant therapy still unde...
Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III Trial [0.03%]
精准肿瘤姑息治疗在抗PD-1/PD-L1免疫疗法的晚期/复发食管癌患者中的作用（ESO上海25）：一项随机III期临床试验
Shengnan Hao,Xiaomin Wang,Huiping Ding et al.
Shengnan Hao et al.
Over half of patients with advanced or recurrent esophageal cancer experience malnutrition, psychological distress, and cancer-related pain, which impair immune function, diminish quality of life, and attenuate responses to immunotherapy. W...
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors [0.03%]
ZEN-31019研究：泽美替尼治疗HER2高表达/扩增或突变的晚期实体瘤II期临床试验方案
Alison M Schram,John J Park,Antoine Italiano et al.
Alison M Schram et al.
Human epidermal growth factor receptor 2 (HER2, encoded by ERBB2) alterations are known oncogenic drivers in many solid tumors. Zongertinib is a novel, oral, irreversible, HER2-selective tyrosine kinase inhibitor that spares wild-type epide...
Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study [0.03%]
ELM-2研究：奥德鲁奈马布治疗复发或难治性滤泡淋巴瘤的通俗版本总结报告
Jose C Villasboas,Michelle Poon,Monica Tani et al.
Jose C Villasboas et al.
Nivolumab plus chemotherapy in Asian people with advanced or recurrent stomach or gastroesophageal junction cancer (ATTRACTION-4 study): a plain language summary [0.03%]
纳武利尤单抗联合化疗治疗晚期或复发性胃癌或胃食管结合部癌（ATTraction-4研究）：简易概述
Li-Tzong Chen,Yoon-Koo Kang,Min-Hee Ryu et al.
Li-Tzong Chen et al.
Comparison of concurrent chemoradiotherapy followed by immunotherapy and induction chemoimmunotherapy followed by radiotherapy in unresectable stage III NSCLC: a retrospective cohort study [0.03%]
不可切除的III期非小细胞肺癌患者序贯放化疗联合免疫治疗和诱导化疗联合免疫治疗后放疗的对比研究：一项回顾性队列研究
Qinhao Xu,Yana Qi,Xiaoyang Zhai et al.
Qinhao Xu et al.
Background: Concurrent chemoradiotherapy followed by immune consolidation therapy (cCRT+IO, the PACIFIC regimen) is the standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). However, the optima...